Six Eminent Cancer Researchers Advise Agendia
AMSTERDAM, October 29 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics has appointed six members to its Clinical and Scientific Advisory Board. The newly established Clinical and Scientific Advisory Board is comprised of internationally-recognized scientists with research and clinical expertise. The advisors review early research programs and provide critical evaluations from academic and clinical perspectives.
Piet Borst (chair), M.D., PhD, CBE, For Mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands
Jose Baselga M.D., Professor of Medicine and Chairman of the medical oncology service, Vall d'Hebron University Hospital, Barcelona, Spain
Matt van de Rijn, M.D., Ph.D, Professor of Pathology, Stanford University, School of Medicine, Stanford, CA, USA
David Kerr M.D., Professor of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, UK
C. Kent Osborne, M.D., Professor of Medicine and, Director, Breast Center Baylor College of Medicine, Houston, Texas, USA, Director, Dan L. Duncan Cancer Center at Baylor College of Medicine
Joe W. Gray, Ph.D., Director, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA and Professor UCSF Comprehensive Cancer Center.
"We are very pleased that this outstanding group of scientist-clinicians has agreed to join Agendia's clinical and scientific advisory board", says Prof. dr. Rene Bernards, Chief Scientific Officer at Agendia. "Their insights into the clinical needs of cancer patients will help us to tailor our product portfolio to best serve patients and their doctors to optimize the treatment for each individual patient."
"The addition of these six distinguished scientists and clinicians will
|SOURCE Agendia BV|
Copyright©2007 PR Newswire.
All rights reserved